PD-L1 positive lympho-epithelial lesions in inflammatory prostate.
Journal
Histology and histopathology
ISSN: 1699-5848
Titre abrégé: Histol Histopathol
Pays: Spain
ID NLM: 8609357
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
pubmed:
8
6
2022
medline:
12
10
2022
entrez:
7
6
2022
Statut:
ppublish
Résumé
Ductal epithelial changes (lympho-epithelial lesions-LEL) in prostatic chronic inflammation (CI) are not well studied so far. to investigate LEL immediately adjacent to prostatic CI. We studied LEL in 144 prostatic surgical and autopsy specimens in various types of prostatic CI: NIH-category IV prostatitis (histologic prostatitis-HP), nonspecific granulomatous prostatitis (NSGP), and the reactive lymphoid infiltrates in the vicinity of benign prostatic hyperplasia (BPH) and prostate adenocarcinoma (PCa). CI is scored as low and high grade (LG, HG) according to the severity of inflammation. LEL was identified in all types of prostatic specimens and in all types of prostatic CI: in 70.9% of patients with HP; in 100% of cases with NSGP; in 68.7% and in 80% adjacent to BPH and PCa respectively. Statistical analysis showed a significant correlation of the presence of LEL with HG CI (p<0.001). LEL showed strong membranous PD-L1 expression. The study presents the first attempt to examine LEL in inflammatory human prostate. PD-L1 positive LEL have no diagnostic organ specificity, although they are a constant histological finding in HG prostatic CI. LEL, inducible after birth by CI, are an integral part of prostate-associated lymphoid tissue (PALT) and of the inflammatory prostatic microenvironment.
Identifiants
pubmed: 35670049
pii: HH-18-479
doi: 10.14670/HH-18-479
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
749-755Informations de copyright
©The Author(s) 2022. Open Access. This article is licensed under a Creative Commons CC-BY International License.
Références
lumenfeld W., Tucci S. and Narayan P. (1992). Incidental lymphocytic prostatitis: selective involvement with non-malignant glands. Am. J. Surg. Pathol. 16, 975-981.
pubmed: 1415905
Cruickshank A.H. (1965). Benign lymphoepithelial lesion to be distinguished from adenolymphoma. J. Clin. Pathol. 18, 391-400.
pmcid: PMC472965
pubmed: 14318686
Chulkina M., Beswick E.J. and Pinchuk I.V. (2020). Role of PD-L1 in gut mucosa tolerance and chronic inflammation. Int. J. Mol. Sci. 21, 9165.
pmcid: PMC7730745
pubmed: 33271941
Delongchamps N.B., de la Roza G., Chandan V., Jones R., Sunheimer R., Threatte G., Jumbelic M. and Haas G.P. (2008). Evaluation of prostatitis in autopsied prostates: is chronic inflammation more associated with BPH or cancer? J. Urol. 179, 1736-1740.
pmcid: PMC2661538
pubmed: 18343414
De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake CG., Nakai Y., Isaacs W.B. and Nelson W.G. (2007). Inflammation in prostate carcinogenesis. Nat. Rev. Cancer. 7, 256-269.
pmcid: PMC3552388
pubmed: 17384581
Di Carlo E., Magnasco S., D`Antuono T., Tenaglia R. and Sorrentino C. (2007). The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCLI3 and CCL2I. Prostate 67, 1070-1080.
pubmed: 17474076
Dikov D., Bachurska S., Staikov D. and Sarafian V. (2015). Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate. Prostate 75, 1074-1084.
pubmed: 25917232
Dikov D.I., Koleva M.S., Boivin J.F., Lisner T., Belovezhdov V.T. and Sarafian V. (2020). Histopathology of nonspecific granulomatous prostatitis with special reference to eosinophilic epithelial metaplasia: Pathophysiologic, diagnostic and differential diagnostic correlation. Indian J. Pathol. Microbiol. 63 (Supplement), S34-S40.
pubmed: 32108624
Giday S.A., Khashab M.A., Buscaglia J.M., Krishnamurty D.M., Chen T., Kalloo A.N., Canto MI., Okolo P.I., Hruban R.H. and Jagannath S.B. (2011). Autoimmune pancreatitis: current diagnostic criteria are suboptimal. J. Gastroenterol. Hepatol. 26, 970-973.
pubmed: 21299615
Keir M.E., Butte M.J., Freeman G.J. and Sharpe A.H. (2008). PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677- 704.
pubmed: 18173375
Kobayashi M., Kawano S., Hatachi S., Kurimoto C., Okazaki T., Iwai Y., Honjo T., Tanaka Y., Minato N., Komori T., Maeda S. and Kumagai S. (2005). Enhanced expression of programmed death-1 (PD-1)/PD- L1 in salivary glands of patients with Sjögren's syndrome. J. Rheumatol. 32, 2156-2163.
pubmed: 16265694
Koleva M., Dikov D., Belovejdov V. and Sarafian V. (2019). Expression of MUC1 in eosinophilic metaplasia of the prostate. Prostate 79, 622-627.
pubmed: 30652335
Martin A.M., Nirschl T.R., Nirschl C.J., Francica B.J., Kochel C.M., van Bokhoven A., Meeker A.K., Lucia M.S., Anders R.A., De Marozo A.M and Drake C.G. (2015). Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis.18, 325-332.
pmcid: PMC4641011
pubmed: 26260996
Matias-Guiu X and Esquius J. (1991). Lymphoepithelial lesion in the thyroid. A non-specific histological finding. Pathol. Res. Pract. 187, 296-300.
pubmed: 2068014
McNeal J.E. (1968). Regional morphology and pathology of the prostate. Am J. Clin. Pathol. 49, 347-357.
pubmed: 5645095
Nickel J.C., True L.D., Krieger J.N., Berger R.E., Boag A.H and Young I.D. (2001). Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 87, 797-805.
pubmed: 11412216
Péricart S., Syrykh C., Amara N., Franchet C., Malavaud B., Gaulard P., Girard J.P., Ysebaert L., Laurent C. and Brousset P. (2020). Exclusive B-cell phenotype of primary prostatic lymphomas: a potential role of chronic prostatitis. Histopathology 76, 767-773.
pubmed: 31825109
Sfanos K.S., Yegnasubramanian S., Nelson W.G. and De Marozo A.M. (2018). The inflammatory microenvironment and microbiome in prostate cancer development. Nat. Rev. Urol. 15, 11-24.
pubmed: 29089606
Sung H.H., Castro I., González S., Aguilera S., Smorodinsky N.I., Quest Afg., Bahamondes V., Alliende C., Cores J., Molina C., Urzua U., Barrera M.J., Hermozo M., Herrera L., Leyton C. and Gonzales M.J. (2015). MUC1/SEC and MUC1/Y overexpression is associated with inflammation in Sjögren's syndrome. Oral Dis. 21, 730-738.
pubmed: 25757505
Taki C., Kitajima S., Sueyoshi K., Yonezawa S., Tanaka S., Sakoda K., Irimura T., Sato E. and Goto M. (2002). MUC1 mucin expression in follicular dendritic cells and lymphoepithelial lesions of gastric mucosa-associated lymphoid tissue lymphoma. Pathol. Int. 52, 691- 701.
pubmed: 12685546
Valdez R., Thorson J., Finn W.G., Schnitzer B. and Kleer C.G. (2003). Lymphocytic mastitis and diabetic mastopathy: a molecular, immunophenotypic, and clinicopathologic evaluation of 11 cases. Mod. Pathol. 16, 223-228.
pubmed: 12640102